EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> NEC and Vaximm teamed up to develop personalized cancer vaccines. The project will make use of NEC’s artificial intelligence technology. Statement

> Leo Pharma exercised its option on compounds identified by HitGen. The decision marks a milestone in the relationship between the companies that began in 2015. Release

> Compugen posted initial phase 1 data on its anti-PVRIG antibody. The trial detected early signs of efficacy in microsatellite stable colorectal cancer. Statement
 
> Lytix Biopharma formed a clinical collaboration with Iovance Biotherapeutics. The companies will test Lytix’s oncolytic peptide in combination with Iovance’s T-cell therapy. Release

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

> Poxel said FDA feedback supports its plan to use the 505(b)(2) pathway to file for approval in nonalcoholic steatohepatitis. The French biotech plans to rely on Actos data in its filing. Statement

> Lunac Therapeutics spun out of the University of Leeds with £2.7 million ($3.5 million) in series A funding. The first close of the round will support work on anticoagulants. Release 

Suggested Articles

Barely two months after seeing Corvidia through a $2.1 billion acquisition, Marc de Garidel is back in the saddle, this time as CEO of AZTherapies.

French biotech Genfit is on its way out of fatty liver R&D after a phase 3 flop, but compatriot Poxel is on its way up with a phase 2 win.

Genentech committed $200 million in upfront and near-term payments, plus up to $515 million in more distant milestones, for the exclusive rights.